Filtered By:
Specialty: International Medicine & Public Health
Condition: Bleeding
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 274 results found since Jan 2013.
PCV22 Estimating the Reduction in Medical Care Costs Associated with Ticagrelor and Aspirin in Patients with Acute Ischemic Stroke or TIA
The efficacy of ticagrelor 90mg and aspirin (ticagrelor-aspirin) for the prevention of stroke following an ischaemic stroke (IS) or transient ischaemic attack (TIA) was evaluated in the Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death (THALES, NCT03354429) trial. Ticagrelor-aspirin resulted in a 17% reduction in the risk of stroke or death over 30 days versus aspirin, but with more bleeding events. Ticagrelor 90mg is approved to reduce stroke risk in patients with acute IS (NIH Stroke Scale score ≤5) or high-risk TIA by the Food and Drug Administration.
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: P. McEwan, O. Darlington, M. Knutsson, H. Denison, P. Ladenvall, P. Amarenco, S.C. Johnston, S. Evans, S. James, A. Himmelmann, J. Venditto, C. Mellstrom, N. Atreja, A. Tank Source Type: research
Attitudes toward anticoagulant treatment among nonvalvular atrial fibrillation patients at high risk of stroke and low risk of bleed
Conclusion: Results suggest that many AF patients who are at high risk of stroke but at low risk of bleed may not be receiving AC due to potentially inaccurate beliefs about risk. This study also found that AF patients place trust in physicians above other factors such as cost when making treatment decisions. Increased education of patients by physicians on the risks and benefits may be a simple strategy to improve outcomes. Keywords: atrial fibrillation, anticoagulants, stroke risk, bleeding risk, treatment
Source: Patient Preference and Adherence - May 16, 2016 Category: Global & Universal Tags: Patient Preference and Adherence Source Type: research
A new era of stroke prevention in atrial fibrillation: comparing a new generation of oral anticoagulants with warfarin
Traditionally, warfarin has been used to prevent stroke in patients with atrial fibrillation (AF), but data from large, multinational, prospective, randomized studies suggest that novel oral anticoagulants (NOACs) may be suitable alternatives. These include the direct thrombin inhibitor dabigatran and the factor Xa inhibitors rivaroxaban, apixaban, and edoxaban. These data showed that dabigatran 150 mg twice daily was more effective at preventing stroke than warfarin, with similar rates of major bleeding, while rivaroxaban 20 mg once daily was noninferior to warfarin, with no difference in major bleeding rates. In addition...
Source: International Archives of Medicine - October 31, 2013 Category: Global & Universal Authors: Bruce Stambler Source Type: research
Cost effectiveness of left atrial appendage closure versus Warfarin for stroke risk reduction in non-valvular Atrial Fibrillation in CMS patients
Stroke is the most severe and debilitating consequence of atrial fibrillation (AF), with many patients ranking the resultant disability as worse than death. Warfarin, the established first-line therapy, is effective at reducing ischemic stroke, but is associated with increased bleeding risk and lower quality of life (QoL). Left atrial appendage closure (LAAC) with the Watchman Device has been found to be superior to warfarin at reducing risk of stroke in AF patients. This analysis sought to assess the cost effectiveness of LAAC versus warfarin for stroke prevention in non-valvular AF from the perspective of the US Centers ...
Source: Value in Health - May 1, 2015 Category: Global & Universal Authors: V. Reddy, R. Akehurst, S.L. Amorosi, S. Armstrong, S. Beard, C. Knight, C. Taggart, D. Holmes Source Type: research
International study suggests combination therapy may prevent stroke in certain people
(NIH/National Institute of Neurological Disorders and Stroke) Results from an international clinical trial of more than 4880 participants, published in the New England Journal of Medicine, show that combining clopidogrel and aspirin following a small stroke or experiencing minor stroke symptoms decreases risk of a new stroke, heart attack or other ischemic event within 90 days. The combination therapy was also associated with an increase in major bleeding, although many of those episodes were non-fatal and did not occur in the brain.
Source: EurekAlert! - Medicine and Health - May 17, 2018 Category: International Medicine & Public Health Source Type: news
Optimal Choice of Pharmacological Therapy – Prevention of Stroke and Assessment of Bleeding Risk in Patients with Atrial Fibrillation
Conclusions:Novel oral anticoagulants (NOACs) seem to be a better choice as a pharmacological therapy in the treatment of AF, due to a lack of adequate monitoring of patients ’ international normalized ratio (INR) values. CHA2DS2‑VASc and HASBLED scores must be used as a part of routine clinical diagnostics when dealing with patients with AF.Keywords:Atrial fbrillation, hemorrhage, risk, stroke, therapeutics
Source: International Journal of Preventive Medicine - June 3, 2019 Category: International Medicine & Public Health Source Type: research
PCV44 Real-World Assessment of the Use of Anti-platelet Therapy for Recurrent Stroke Prevention in US Patients without Atrial Fibrillation with Recent Ischemic Stroke or Transient Ischemic Attack
This study evaluated current AP treatment patterns in a real-world setting following an initial ischemic stroke (IS) or transient ischemic attack (TIA).
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: E. O'Brien, D. Milentijevic, R. Roychowdhury, S. Mitra, Y.W. Chen Source Type: research
New imaging method may predict risk of post-treatment brain bleeding after stroke
(NIH/National Institute of Neurological Disorders and Stroke) In a study of stroke patients, investigators confirmed through MRI brain scans that there was an association between the extent of disruption to the brain's protective blood-brain barrier and the severity of bleeding following invasive stroke therapy. The results of the National Institutes of Health-funded study were published in Neurology.
Source: EurekAlert! - Medicine and Health - June 17, 2016 Category: Global & Universal Source Type: news
PCV42 Antiplatelet Treatment Patterns for Secondary Stroke Prevention in the United Kingdom
This study evaluated outpatient antiplatelet treatment patterns for secondary stroke prevention (SSP) after first hospitalization for IS/TIA among UK adults without atrial fibrillation (AF).
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: J. Jiang, D. Li, J. Horrow, H. Tamada, A. Kahl, V. Hariharan, A. Avinav, X. Liu, X. Li Tags: Cardiovascular Disorders - Health Service Delivery & Process of Care Source Type: research
EE344 Cost-Effectiveness of a Novel Treatment for Stroke Prevention in Patients with Atrial Fibrillation: Results from an Early Economic Analysis
For many patients with atrial fibrillation (AF) at moderate-to-high risk of stroke, clinically significant bleeding from anticoagulants remains a concern, leading to withholding or discontinuation of anticoagulation. Patients who are unsuitable for or inadequately treated with currently available anticoagulants remain at higher risk for stroke and systemic embolism. This early economic analysis explored the potential cost-effectiveness of a hypothetical new therapy that reduces the risk of stroke in patients with AF who are unsuitable for treatment with currently available anticoagulants.
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: J. Benner, D. Bloomfield, N. Mehta, B.A. Yi Source Type: research
WATCHMAN device gives patients alternative to blood thinners and reduces stroke risk
(MedStar Washington Hospital Center) MedStar Heart & Vascular Institute at MedStar Washington Hospital Center was the first in the Washington metropolitan region to implant the newly approved WATCHMAN Device. The new device is designed to prevent stroke in high-risk patients with atrial fibrillation who are seeking an alternative to blood-thinning medication. Blood thinners are effective in stroke risk reductions for A-fib patients, but many cannot tolerate these drugs because of the risk of bleeding. Now, there's a new option.
Source: EurekAlert! - Medicine and Health - July 2, 2015 Category: Global & Universal Source Type: news
Cost Effectiveness of Apixaban (Novel Oral Anti-Coagulant) Compared with Conventional Therapy for Stroke Prophylaxis among Renal Impaired Patients with Atrial-Fibrillation from Perspective of Us Third Party Payer
Atrial Fibrillation (AF) has been a major risk factor for the development of stroke making anticoagulation therapy necessary. While on prophylaxis treatment, renal impaired patients on conventional anticoagulation (Warfarin) are at an increased risk for major bleeding. Apixaban has been shown to have better safety profile than Warfarin in face to face clinical trial. However, no study were found to have compared the cost effectiveness of Apixaban with Warfarin among renal impaired patients. We attempted to estimate the short term (one year) cost effectiveness of Apixaban compared to Warfarin for stroke prophylaxis among re...
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: A Kumar, W Wu, M Nili Source Type: research
Intensive blood pressure lowering safe for clot-buster-treated stroke patients, but...
(American Heart Association) Rapidly lowering blood pressure beyond recommended targets safely reduced the risk of bleeding as a side effect in stroke patients but did not limit post-stroke disability.
Source: EurekAlert! - Medicine and Health - February 7, 2019 Category: International Medicine & Public Health Source Type: news
Study finds trend toward benefit in using blood-clotting agent for bleeding stroke
(American Heart Association) There are few treatment options for bleeding stroke.There was a trend towards reduced growth of brain bleeds in those treated with the antifibrinolytic agent tranexamic acid within 4.5 hours of stroke onset, compared to those treated with placebo.
Source: EurekAlert! - Medicine and Health - February 21, 2020 Category: International Medicine & Public Health Source Type: news
Rate over time of stroke caused by brain bleeding
(JAMA Network) This observational study looked at the rate and risk factors of stroke caused by bleeding within the brain (intracerebral hemorrhage) between 1948 and 2016 among 10,000 participants in the Framingham Heart Study. There have been conflicting results in other studies on whether the rate of this often deadly type of stroke is changing.
Source: EurekAlert! - Medicine and Health - June 8, 2020 Category: International Medicine & Public Health Source Type: news
